Advances in pharmacotherapy for primary biliary cholangitis / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1188-1191, 2017.
Article
em Zh
| WPRIM
| ID: wpr-613347
Biblioteca responsável:
WPRO
ABSTRACT
The pathogenesis of primary biliary cholangitis (PBC) remains unclear.Ursodeoxycholic acid (UDCA) is currently the only drug approved by the Food and Drag Administration for the treatment of PBC,but some patients have a poor response to UDCA.New therapies can be considered for these patients.This article reviews the advances in drugs for PBC,including 6or-ethyl-chenodeoxycholic acid,fibrates,budesonide,and biological agents,and points out that these drugs bring new hope for PBC patients,but large-scale clinical studies are needed to confirm the long-term efficacy and safety.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Clinical Hepatology
Ano de publicação:
2017
Tipo de documento:
Article